Delivery Order SPE2DB25D9320-SPE2DB25FWFDE
Award Date 9/25/25
Potential Completion Date 10/17/25
Potential Value $2.6K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order valued at $1,547.40 for XOLAIR 75 mg/0.5 ml syringes. The award, issued on September 11, 2025, with an ultimate completion date of October 2, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a delivery order valued at $4,642.20 to DMS Pharmaceutical Group Inc. for XOLAIR 150 MG/ML Syringe on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order was issued without a set-aside designation to the woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. XOLAIR (omalizumab) is a monoclonal antibody used primarily for treating moderate-to-severe allergic asthma and...
- The Defense Logistics Agency awarded a $27,907.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 mL syringes on September 4, 2025, with an ultimate completion date of September 25, 2025. Xolair (omalizumab) is a monoclonal antibody used primarily to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, making this delivery order part of DLA's pharmaceutical supply chain supporting Department of Defense healthcare facilities. The award...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 300 mg/2 ml auto-injector units. The contract, valued at $10,273.38 with a firm fixed-price structure, was awarded on August 14, 2025, with an ultimate completion date of September 5, 2025. This delivery order was issued without a set-aside designation, and performance will take place at the...
- The Defense Logistics Agency awarded a $6,848.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 9, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units with an ultimate completion date of September 30, 2025. This delivery order was issued without a set-aside designation and will be performed in Park Ridge, Illinois, where the vendor is headquartered. Xolair (omalizumab) is a monoclonal antibody injection used primarily in the treatment of...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, valued at $22,325.76 with an ultimate completion date of September 16, 2025, was issued without a set-aside designation on August 25, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on September 11, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $3,094.80. This firm fixed-price delivery order is scheduled for ultimate completion by October 2, 2025, and represents no set-aside designation. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate to severe allergic asthma and chronic idiopathic urticaria, indicating this delivery supports...
- The Defense Logistics Agency (DLA) awarded a $15,474.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml syringes on September 23, 2025. The award, which carries an ultimate completion date of October 15, 2025, represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA valued at approximately $500 million through November 2026. No set-aside designation was applied to this award. XOLAIR...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $37,209.60 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 mL syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order is scheduled for completion by June 11, 2025, with performance taking place at the contractor's Park Ridge facility. This award was issued under...
- The Defense Logistics Agency awarded a delivery order valued at $6,189.60 to DMS Pharmaceutical Group Inc. for XOLAIR 150 MG/ML syringes. This award, issued on September 10, 2025, with an ultimate completion date of October 1, 2025, represents a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will fulfill this order. XOLAIR (omalizumab) is a biologic...